What first‑line antihypertensive should be used in a young woman with asthma and chronic kidney disease (eGFR approximately 46 mL/min/1.73 m²), and how should therapy be monitored?

First-Line Antihypertensive for Young Woman with Asthma and CKD

Start with an ACE inhibitor (or ARB if ACE inhibitor is not tolerated) as first-line therapy, targeting a blood pressure of ≤130/80 mmHg. 1

Rationale for ACE Inhibitor/ARB Selection

The presence of chronic kidney disease (eGFR ~46 mL/min/1.73 m²) is the dominant factor driving medication selection in this patient. The Canadian Hypertension Education Program guidelines explicitly recommend ACE inhibitors as initial therapy for patients with nondiabetic chronic kidney disease (Grade A evidence), with ARBs as the alternative if ACE inhibitors are not tolerated (Grade B evidence). 1, 2

The asthma history does not contraindicate ACE inhibitors or ARBs - these medications do not cause bronchospasm and are safe in asthma patients. Beta-blockers would be the antihypertensive class to avoid in asthma, but they are not first-line for this clinical scenario anyway.

Determining if Proteinuria is Present

Before finalizing the treatment plan, check the urine albumin-to-creatinine ratio (ACR):

• If ACR ≥30 mg/mmol (or urinary protein ≥500 mg/24hr): ACE inhibitor is strongly indicated as first-line therapy (Grade A) 1, 2
• If ACR <30 mg/mmol (non-proteinuric CKD): ACE inhibitor or ARB remains appropriate, though the evidence grade is slightly lower

Building the Antihypertensive Regimen

Most patients with CKD require combination therapy to reach target blood pressure. 1 The algorithmic approach:

1. Start: ACE inhibitor (or ARB if intolerant)
2. Add second agent if BP not at goal: Thiazide diuretic (Grade D recommendation) 1
   • Important caveat: At eGFR 46 mL/min/1.73 m², thiazides still work, but if eGFR drops below ~30 mL/min/1.73 m², switch to a loop diuretic
3. Add third agent if needed: Long-acting dihydropyridine calcium channel blocker 1

Do not combine ACE inhibitor + ARB in non-proteinuric CKD (Grade B recommendation against this). 1

Monitoring Strategy

Initial Monitoring (First 2-4 Weeks After Starting/Adjusting Therapy):

• Serum creatinine and eGFR: Expect a mild decrease in eGFR (up to 30% from baseline) when starting ACE inhibitor/ARB - this is hemodynamic and acceptable. If eGFR drops >30%, consider renovascular disease or volume depletion
• Serum potassium: ACE inhibitors/ARBs can cause hyperkalemia, especially with eGFR <60 mL/min/1.73 m². 3 Check within 1-2 weeks of initiation
• Blood pressure: Confirm therapeutic response

Ongoing Monitoring:

• Every 3-6 months: Serum creatinine, eGFR, potassium, and urine ACR 3
• Blood pressure: Home blood pressure monitoring is valuable for confirming control and detecting white-coat effects
• Annual: Comprehensive metabolic panel to screen for CKD complications (anemia, metabolic acidosis, mineral bone disease) as eGFR declines 3

Critical Pitfalls to Avoid

Hyperkalemia management: If potassium rises to 5.5-6.0 mEq/L, do not automatically discontinue the ACE inhibitor/ARB. These medications provide renal protection and mortality benefit. Instead:

• Reduce dietary potassium intake
• Consider potassium binders (patiromer, sodium zirconium cyclosilicate)
• Ensure adequate diuretic therapy
• Only discontinue if potassium persistently >6.0 mEq/L despite interventions 3

Volume status: Young women may have lower baseline blood pressure. Monitor for orthostatic hypotension, especially when adding diuretics. Measure BP sitting/lying for 5 minutes, then 1-3 minutes after standing. 4

Sick day protocol: Educate the patient to temporarily hold ACE inhibitor/ARB during acute illnesses with vomiting, diarrhea, or reduced oral intake to prevent acute kidney injury. 5